Voyageur Pharmaceuticals (TSXV:VM) EV-to-EBIT : -4.96 (As of May. 27, 2024)

Voyageur Pharmaceuticals EV-to-EBIT Chart

Voyageur Pharmaceuticals Annual Data
	Trend	Dec14	Dec15	Nov16	Nov17	Nov18	Nov19	Nov20	Nov21	Nov22	Nov23
EV-to-EBIT		Get a 7-Day Free Trial					-9.56	-2.78	-4.10	-4.60	-3.83

Voyageur Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial															-6.11	-4.60	-3.52	-3.83	-7.00

Competitive Comparison of Voyageur Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyageur Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's EV-to-EBIT falls into.

Voyageur Pharmaceuticals EV-to-EBIT Calculation

Voyageur Pharmaceuticals's EV-to-EBIT for today is calculated as:

Voyageur Pharmaceuticals's current Enterprise Value is C$6.73 Mil.
Voyageur Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals  (TSXV:VM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Voyageur Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Voyageur Pharmaceuticals's Enterprise Value for the quarter that ended in Feb. 2024 was C$9.51 Mil.
Voyageur Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyageur Pharmaceuticals (TSXV:VM) Business Description